# Regeneron Pharmaceuticals, Inc. – Consensus ‘buy’ rating and 5.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/regeneron-pharmaceuticals-inc.consensus-buy-rating-and-5.5-upside-potential/4121136295
- Published: 2023-12-15T12:16:45+00:00
- Author: Charlotte Edwards

**Regeneron Pharmaceuticals, Inc.** which can be found using ticker (REGN) have 
now 22 market analysts covering the stock. The analyst consensus now points to a
rating of ‘buy’. The target price High/Low ranges between $1,066.00 and $680.00 
calculating the average target price we see $924.50. Given that the stocks previous
close was at $876.12 this would indicate that there is a potential upside of 5.5%.
It’s also worth noting that there is a 50 day moving average of $816.11 and the 
200 day MA is $788.12. The company has a market cap of 95.39B. The stock price for
the company is currently $876.00 USD

 The potential market cap would be $100,659,641,176 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 24.99, revenue per share of $122.63
and a 9.21% return on assets.

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers,
invents, develops, manufactures, and commercializes medicines for serious diseases.
Its commercialized medicines and product candidates in development are designed 
to help patients with eye diseases, allergic and inflammatory diseases, cancer, 
cardiovascular and metabolic diseases, pain, hematologic conditions, infectious 
diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection,
Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab)
Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza(
evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection,
ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept)
Injection for Intravenous Infusion. The Company also provides Expresse service assurance
and CloudCheck WiFi experience management solutions.

Share on:
